Nabriva Therapeutics CFO and interim CEO depart; restructuring consultants take over

Nabriva Therapeutics plc

CFO Daniel Dolan separated June 30, 2023; interim CEO/GC J. Christopher Naftzger separated July 7, 2023.
Both executives receive 12 months base salary, COBRA premium payments, 100% target bonus, accelerated equity vesting.
H. Michael Hogan appointed CEO and Dave Maggio appointed CFO effective July 7 and June 30 respectively, via Armanino LLP consulting agreement.
Hogan and Maggio are partners/directors at Armanino, a restructuring firm; consulting fees $425-$650/hr and $375-$495/hr respectively.
Appointments part of Cash Preservation Plan to wind down operations; consulting agreements expire Dec 31, 2023.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

J. Christopher Naftzger

Interim Chief Executive Officer, General Counsel and Secretary

Nabriva Therapeutics plc

Effective: 2023-07-07
Filed: July 7, 2023, 7:59 PM ET

and J. Christopher Naftzger, the Company’s Interim Chief Executive Officer, General Counsel and Secretary, entered into a Separation and Release of Claims Agreement with Nabriva Therapeutics US, Inc., a wholly-owned subsidiary of the Company, providing for their separation from employment with the Company effective June 30, 2023 (the “Dolan Separation Date”), in the case of Mr. Dolan, and July 7, 2023, in the case of Mr. Naftzger.

Departed

Daniel Dolan

Chief Financial Officer

Nabriva Therapeutics plc

Effective: 2023-06-30
Filed: July 7, 2023, 7:59 PM ET

each of Daniel Dolan, the Company’s Chief Financial Officer, and J. Christopher Naftzger, the Company’s Interim Chief Executive Officer, General Counsel and Secretary, entered into a Separation and Release of Claims Agreement with Nabriva Therapeutics US, Inc., a wholly-owned subsidiary of the Company, providing for their separation from employment with the Company effective June 30, 2023 (the “Dolan Separation Date”), in the case of Mr. Dolan, and July 7, 2023, in the case of Mr. Naftzger.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

J. Christopher Naftzger departed as Interim Chief Executive Officer, General Counsel and Secretary at Nabriva Therapeutics plc.

Action: separated
Role: Interim Chief Executive Officer, General Counsel and Secretary

Exact text from the filing

and J. Christopher Naftzger, the Company’s Interim Chief Executive Officer, General Counsel and Secretary, entered into a Separation and Release of Claims Agreement with Nabriva Therapeutics US, Inc., a wholly-owned subsidiary of the Company, providing for their separation from employment with the Company effective June 30, 2023 (the “Dolan Separation Date”), in the case of Mr. Dolan, and July 7, 2023, in the case of Mr. Naftzger.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Dolan departed as Chief Financial Officer at Nabriva Therapeutics plc.

Action: separated
Role: Chief Financial Officer

Exact text from the filing

each of Daniel Dolan, the Company’s Chief Financial Officer, and J. Christopher Naftzger, the Company’s Interim Chief Executive Officer, General Counsel and Secretary, entered into a Separation and Release of Claims Agreement with Nabriva Therapeutics US, Inc., a wholly-owned subsidiary of the Company, providing for their separation from employment with the Company effective June 30, 2023 (the “Dolan Separation Date”), in the case of Mr. Dolan, and July 7, 2023, in the case of Mr. Naftzger.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-23-079156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.